4.71% 0.0008

Galera Therapeutics Inc (GRTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GRTX Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Galera Therapeutics Inc Stock (GRTX) Company Profile

Galera Therapeutics Inc

Healthcare (1150)

Biotechnology (644)

Prossima data di guadagno

Ultimi documenti SEC

GRTX's Discussions on Twitter

Confronta GRTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GRTX Galera Therapeutics Inc	0.0178	0	0	-69.68M	-48.93M	-1.89
VRTX Vertex Pharmaceuticals Inc	391.36	100.82B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	461.24	60.45B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	575.06	60.69B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	752.32	46.32B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	327.20	36.58B	3.81B	-644.79M	-669.77M	-6.24

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-10	Downgrade	Piper Sandler	Overweight → Neutral
2021-10-19	Downgrade	BTIG Research	Buy → Neutral
2021-10-19	Downgrade	BofA Securities	Buy → Underperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2020-12-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-07	Iniziato	H.C. Wainwright	Buy
2019-12-02	Iniziato	BTIG Research	Buy
2019-12-02	Iniziato	BofA/Merrill	Buy
2019-12-02	Iniziato	Citigroup	Buy
2019-12-02	Iniziato	Credit Suisse	Neutral

Mostra tutto

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Stock (GRTX) Company Profile

Confronta GRTX con altri titoli

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

North American Morning Briefing : Stock Futures -2- - MarketScreener

Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com

Galera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener

Galera Therapeutics, Inc. SEC 10-Q Report - TradingView

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Lelezard

Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - The Manila Times

Oral Mucositis Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com

Oral Mucositis Drugs Market Set to Witness Significant Growth - openPR.com

U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com

Radiation-induced Esophagitis Treatment Market Size in 7MM - openPR.com

Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire

Galera Therapeutics extends agreement deadline - Investing.com Australia

Galera Therapeutics extends agreement deadline By Investing.com - Investing.com South Africa

Galera Therapeutics Inc. (GRTX) reports earnings - Quartz

Radiotherapy Induced Oral Mucositis Treatment Market Size - openPR.com

Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights

Galera Therapeutics holds annual stockholder meeting - Investing.com

Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research

Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - VISTA.Today

Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech

Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Nasdaq

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace

Twelve option delistings on December 23rd - TipRanks

Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - VISTA Today

The 2024 Biotech Graveyard - Fierce Biotech

Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com

Galera stockholders reject liquidation plan - Investing.com

UroGen Appoints Chris Degnan as Chief Financial Officer - Yahoo Finance

2 Kite vets fly over to Kyverna Therapeutics—Chutes & Ladders - Fierce Biotech

Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda - GlobeNewswire

Galera Therapeutics faces Nasdaq delisting - Investing.com

"Trimming the Fat or Losing the Muscle? August 2024’s Biotech Layoff Frenzy Signals Strategic 'Adjustments' in the Name of Efficiency" - BioSpectrum Asia

Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo

Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire

Galera Therapeutics settles lawsuit for $975,000 - Investing.com

Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive

Why Galera Therapeutics (GRTX) Stock Is Nosediving - TradingView

Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics - Hunt Scanlon Media

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - TipRanks

Galera Therapeutics Implements Stockholder Rights Plan to Shield Investor Interests - MyChesCo

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer - PR Newswire

Oral Mucositis Treatment Market Size & Share Report, 2032 - Global Market Insights

Radiotherapy Induced Oral Mucositis Treatment Market, 2032 - Global Market Insights

Opthalmic Industry Veteran Joins Nacuity Pharmaceuticals’ Board - Dallas Innovates

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates - Yahoo Finance

Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying - TradingView

2023 gainers and losers: Positive trial outcomes and M&As propel biopharma stocks to strong finish - BioWorld MedTech

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update - Yahoo Finance

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a GRTX